ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Trading Activity – CEO Sold 2,983 shares of Stock

0

Insider Trading Activity For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Stephen Davis , CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reportedly Sold 2,983 shares of the company’s stock at an average price of 39.65 for a total transaction amount of $118,275.95 SEC Form

Insider Trading History For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

  • On 4/11/2013 Thomas H Aasen, CFO, sold 40,000 with an average share price of $11.06 per share and the total transaction amounting to $442,400.00.
  • On 4/12/2013 Glenn Baity, VP, sold 60,000 with an average share price of $12.42 per share and the total transaction amounting to $745,200.00.
  • On 5/15/2013 Felix Baker, Director, bought 1,993,000 with an average share price of $12.50 per share and the total transaction amounting to $24,912,500.00.
  • On 6/5/2013 Felix Baker, Director, bought 2,340,314 with an average share price of $14.34 per share and the total transaction amounting to $33,560,102.76.
  • On 8/13/2013 Uli Hacksell, CEO, sold 52,771 with an average share price of $20.14 per share and the total transaction amounting to $1,062,807.94.
  • On 8/13/2013 Thomas Aasen, CFO, sold 60,000 with an average share price of $20.15 per share and the total transaction amounting to $1,209,000.00.
  • On 8/26/2013 Mary Ann Gray, Director, sold 15,000 with an average share price of $20.68 per share and the total transaction amounting to $310,200.00.
  • Analyst Ratings History For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

    • On 8/9/2018 JMP Securities Lower Price Target of rating Market Outperform to Market Outperform with a price target of $50.00 to $27.00
    • On 11/16/2018 UBS Group Initiated Coverage of rating Neutral with a price target of $39.00
    • On 5/31/2019 Raymond James Boost Price Target of rating Strong-Buy with a price target of $40.00 to $43.00
    • On 7/31/2019 Bank of America Set Price Target of rating Buy with a price target of $31.00
    • On 9/9/2019 Needham & Company LLC Boost Price Target of rating Buy with a price target of $34.00 to $60.00
    • On 9/9/2019 Cowen Reiterated Rating Buy with a price target of $66.00
    • On 9/9/2019 Piper Jaffray Companies Boost Price Target of rating Overweight with a price target of $35.00 to $56.00

    Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
    Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 39.98 up +0.080 0.20% with 1281000 shares trading hands.